Company intelligence / Profile preview
Asher Biotherapeutics
South San Francisco, California, United States
- Ownership
- Private
- Employees
- ~20
- Development stage
- Other
01
Overview
Initial clinical data for etakafusp alfa (formerly AB248) shows compelling anti-tumor activity and a differentiated safety profile as a CD8+ T cell selective IL-2 therapy in ongoing Phase 1a/1b clinical trials[3][5].
- Therapeutic areas
- OncologyInfectious DiseasesImmunology
- Modalities
- CytokineBiologic
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →03
Partnerships
AstraZeneca (clinical supply agreement to test combinations in NSCLC and small cell lung cancer)[1][3]Bristol Myers Squibb (investment/strategic relationship)[1]
Beyond the preview
Go deeper on Asher Biotherapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Asher Biotherapeutics.